AzTrials
AzTrials

Occupational ExposureNCT06323603

Biomonitoring of Occupationally Populations Exposed to Micro and Nanoplastic

An observational study of Occupational Exposure and Genotoxicity, run by Ricard Marcos at 4 sites in 2 countries.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The biomonitoring study aims to evaluate genotoxic damage and other parameters of exposure in different occupational exposed populations that work directly with different plastics. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Occupational Exposure, Genotoxicity, Damage Dna
What is being tested?
Micro and nanoplastic
How many people
45 participants
Where
4 sitesin 2 countries
Study dates
30 Jun 2023to Sep 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: The study aims to determine whether workers occupationally exposed to different plastics show increased genomic damage, changes in cytokine expression and/ or microbiota. Moreover, the levels of macro/microplastics in different body fluids will be characterized. Different European populations dedicated to the recycling of plastics and the production of non-woven textiles will be used, as well as a control group that will match according to the characteristics of the populations. At least 50 workers from each of the participating industries will be used to demonstrate a higher exposure MNPLs level and, therefore, an increased health risk.

Who may be able to join

  • Aged over 18 years.
  • Healthy subjects defined by the absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, haematology, blood chemistry, and urine analysis.
  • Able to participate and willing to give written informed consent and to comply with the study restrictions.
  • Have been working at the company for the last 48 months

Who cannot join

  • Workers decline participation
  • Legal incapacity or inability to understand or comply with the requirements of the study.
  • Any hierarchical subordination to the PI
  • Clinically significant findings as determined by medical history taking, physical examination, ECG, and vital signs.
  • Submitted to X-ray in the three previous months

Trial locations and contacts

4 sites in 2 countries.

Alba Hernández, Professor contact

+34 93 581 4702

alba.hernandez@uab.cat

4 sites in 2 countries

Spain3 sites, 1 recruiting
  • Recycling company

    Alicante

    Completed
  • Textile Industry

    Alicante

    Completed
  • Control recruitment

    Barcelona

    Susana Pastor

    Recruiting

Other trials in Spain

Finland1 site
  • Textile industry

    Helsinki

    Completed

Other trials in Finland

About this study

The biomonitoring study aims to evaluate genotoxic damage and other parameters of exposure in different occupational exposed populations that work directly with different plastics.

Read the detailed description

The exponential increase in the production and use of plastic goods translates into a parallel increase of environmental plastic waste that is continuously degraded into micro and nanoplastics (MNPLs). Information on their effects on human health is still preliminary, especially regarding human biomonitoring studies, thus more information is required for risk assessment evaluation.

This observational study aims to evaluate the exposure to MNPLs in human populations occupationally exposed to different types of plastics (fibers and plastic waste). The study will evaluate the effect of exposure to MNPLs (genotoxic and microbiota effects) in different body samples (blood, exfoliated buccal cells, urine,and feces) and also will use those samples to evaluate the presence of MNPLs.

Being tested
Micro and nanoplastic
Keywords
Biomonitoring, Genotoxic damage, Micro and nanoplastic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Micro and nanoplasticOther

    Biological samples will be obtained to evaluate the different biomarkers selected

Study groups in NCT06323603
Study groupRoleWhat they receive
1. Textile industry workersWorkers from the textile industry, that manufactures non-wovens fibers
Receives: Other: Micro and nanoplastic
2. Plastic Recycling WorkersWorkers involved in recycling and waste management of plastic
Receives: Other: Micro and nanoplastic
3. ControlsControl group that will match the characteristics of grup 1 and 2

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Characterization of macro and nanoplastics

    The characterization of macro and nanoplastics will be done by Raman spectrosmicroscopy and FTIR (From exhaled breath condensate, blood and urine)

    Measured: Up to 1 year

  2. Genotoxic evaluation by the Micronucleus assay

    Blood and buccal cells will be collected from donors to check for the presence of genotoxic permanent damage

    Measured: Up to 1 year

  3. Genotoxic evaluation by the Comet assay

    Blood will be analysed to check for the presence of genotoxic primary damage

    Measured: Up to 1 year

  4. Cytokine release

    Plasma will be analysed to check for the presence of cytokines

    Measured: Up to 1 year

  5. Microbiota analysis from feces by MinIOn

    Feces will be analysed to check for variations in microbiota in the exposed and control groups

    Measured: up to 1 year

Secondary outcomes (1)
  1. Analyses of surrogate biomarkers

    Different metabolites will be analysed in the urine of participants, as an indirect measure to detect plastic exposure (p.eg. ftalates).

    The selection of the metabolite will depend of other analyses done on the project.

    Measured: Up to 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Mar 2024
  2. Study start30 Jun 2023
  3. Primary completionJun 2024 (estimated)
  4. Study completionSep 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
45 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06323603
Sponsor's protocol ID
3-1
Status last verified
Mar 2024
First submitted
14 Mar 2024
Last updated
25 Mar 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Occupational Exposure and Genotoxicity, run by Ricard Marcos at 4 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 25 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in Spain, Finland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Alba Hernández, Professor (+34 93 581 4702, alba.hernandez@uab.cat), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Characterization of macro and nanoplastics (time frame: Up to 1 year). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Mar 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in